Results 251 to 260 of about 444,898 (308)

Single Centre Experience With the Balloon‐Expandable Myval Transcatheter Aortic Valve System in Patients With Bicuspid Anatomy: 1 Year Follow‐Up

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Transcatheter aortic valve implantation (TAVI) in bicuspid aortic valve (BAV) anatomy remains challenging due to anatomical complexity and limited trial data. New‐generation balloon‐expandable valves, such as Myval, require further evaluation in this subgroup.
Balázs Magyari   +11 more
wiley   +1 more source

Myocardial injury in patients with acute ischemic stroke: Prevalence and types of triggers of myocardial demand ischemia. [PDF]

open access: yesEur Stroke J
Stengl H   +11 more
europepmc   +1 more source

GLP‐1 Receptor Agonists in Metabolic Dysfunction‐Associated Steatotic Liver Disease: Bridging Hepatic and Cardiovascular Outcomes

open access: yesChronic Diseases and Translational Medicine, EarlyView.
Endogenous GLP‐1 and exogenous GLP‐1 RAs activate GLP‐1R‐expressing vagal afferents in the portal vein, projecting to the nucleus tractus solitarius (NTS). This input engages brainstem–hypothalamic circuits that regulate metabolic homeostasis. Hypothalamic efferent vagal output to the liver suppresses lipogenesis, enhances triglyceride export, and ...
Gabriel Amorim Moreira Alves   +8 more
wiley   +1 more source

Inflammatory response to elective percutaneous coronary intervention is related to myocardial injury. [PDF]

open access: yesEinstein (Sao Paulo)
Frisso PTC   +10 more
europepmc   +1 more source

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy